Clinical trial
An Exploratory, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Orally Administered GLPG2737 for 52 Weeks, Followed by an Open-label Extension Period of 52 Weeks in Participants With Autosomal Dominant Polycystic Kidney Disease
NCT04578548 is registered in ClinicalTrials.gov with Lakefront Biotherapeutics NV as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Exploratory, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Orally Administered GLPG2737 for 52 Weeks, Followed by an Open-label Extension Period of 52 Weeks in Participants With Autosomal Dominant Polycystic Kidney Disease
- Lead sponsor
- Lakefront Biotherapeutics NV
- Phase
- Phase 2
- Overall status
- Terminated
- Start date
- November 10, 2020
- Completion date
- April 4, 2023
- Enrollment
- 66 (actual)
- Sites
- 20
Conditions
As the registry lists them; a condition with its own page is linked.
autosomal dominant polycystic kidney disease